Bienvenu(e) sur le site de l'Institut Necker Enfants Malades

de la science fondamentale :
à la recherche translationnelle :
Guillaume Canaud

Focus

Pour plus d'informations, merci de consulter notre site : http://canaudlab.recherche.parisdescartes.fr

Prix et distinctions de l'équipe

Guillaume Canaud :

  • 2015 - Prix Jeune Chercheur de la Fondation Bettencourt Schueller
  • 2014 - Prix Jeune Chercheur de la Phillip Foundation
  • 2014 - Prix Jeune Chercheur de la Société Francophone de Néphrologie et de Dialyse
  • 2017 - Prix de recherche de la Fondation Tourre contre le cancer
  • 2018 - Prix Jeune chercheur de la Fondation Cino Del Duca
  • 2018 - Grand Prix Jean Pierre Lecocq de l'Académie des Sciences
  • 2019 - Grand Prix Jean Hamburger de la ville de Paris
  • 2019 - Grand Prix de l'Association Robert Debré pour la Recherche Médicale
  • 2019 - 1er Prix de la Fondation Line Renaud-Loulou Gasté pour la recherche médicale
  • 2019 - Grand Prix Eloi Collery de l'Académie de Médecine

Quitterie Venot :

  • 2019 - Prix Grandes Avancées Biologiques de l’Académie des Sciences
  • 2019 - Prix Nezelof Imagine

5 main publications

  • Yamaguchi J, Canaud G.
    Vascular endothelial growth factor backfiltration in the glomerulus: an intriguing mechanism.
    Nephrol Dial Transplant. 2018 Apr 30.
  • Venot Q, Blanc T, Hadj Rabia S, Berteloot L, Ladraa S, Duong JP, Blanc E, Johnson SC, Hoguin C, Boccara O, Sarnacki S, Boddaert N, Pannier S, Martinez F, Magassa S, Yamaguchi J, Knebelmann B, Merville P, Grenier N, Joly D, Cormier-Daire V, Michot C, Bole-Feysot C, Picard A, Soupre V, Lyonnet S, Sadoine J, Slimani L, Chaussain C, Laroche-Raynaud C, Guibaud L, Broissand C, Amiel, Legendre L, Terzi F, Canaud G.
    Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
    Nature 2018 Jun;558(7711):540-546 with commentary Jun;558(7711):523-526
  • Johnson SC, Martinez F, Bitto A, Gonzalez B, Tazaerslan C, Cohen C, Delaval L, Timsit J, Knebelmann B, Terzi F, Mahal T, Zhu Y, Morgan PG, Sedensky MM, Kaeberlein M, Legendre C, Suh Y, Canaud G.
    mTOR inhibition Attenuates Human Mitochondrial Encephalopathy with Lactic Acidosis and Stroke-like Episodes (MELAS).
    Kidney Int. 2019 Feb;95(2):455-466
  • Canaud G, Brooks CR, Kishi S, Taguchi K, Nishimura K, Magassa S, Scott A, Hsiao LL, Ichimura T, Terzi F, Yang L and Bonventre JV.
    Cyclin G1 and TASCC regulate pro-fibrotic secretory phenotypes in kidney tubule cells in the G2/M phase of the cell cycle.
    Sci Transl Med. 2019 Jan 23;11(476)
  • Isnard P, Kula T, Avettand Fenoel V, Anglicheau D, Terzi F, Legendre C, Elledge S, Canaud G. Temporal virus serological profiling of kidney graft recipients using VirScan.
    Proc Natl Acad Sci USA. 2019 May 13

2019

  • Isnard P, Kula T, Avettand Fenoel V, Anglicheau D, Terzi F, Legendre C, Elledge S, Canaud G.
    Temporal virus serological profiling of kidney graft recipients using VirScan.
    Proc Natl Acad Sci USA. 2019 May 13
  • Canaud G, Brooks CR, Kishi S, Taguchi K, Nishimura K, Magassa S, Scott A, Hsiao LL, Ichimura T, Terzi F, Yang L and Bonventre JV.
    Cyclin G1 and TASCC regulate pro-fibrotic secretory phenotypes in kidney tubule cells in the G2/M phase of the cell cycle.
    Sci Transl Med. 2019 Jan 23;11(476)
  • Johnson SC, Martinez F, Bitto A, Gonzalez B, Tazaerslan C, Cohen C, Delaval L, Timsit J, Knebelmann B, Terzi F, Mahal T, Zhu Y, Morgan PG, Sedensky MM, Kaeberlein M, Legendre C, Suh Y, Canaud G.
    mTOR inhibition Attenuates Human Mitochondrial Encephalopathy with Lactic Acidosis and Stroke-like Episodes (MELAS).
    Kidney Int. 2019 Feb;95(2):455-466
  • 2018

  • Venot Q, Blanc T, Hadj Rabia S, Berteloot L, Ladraa S, Duong JP, Blanc E, Johnson SC, Hoguin C, Boccara O, Sarnacki S, Boddaert N, Pannier S, Martinez F, Magassa S, Yamaguchi J, Knebelmann B, Merville P, Grenier N, Joly D, Cormier-Daire V, Michot C, Bole-Feysot C, Picard A, Soupre V, Lyonnet S, Sadoine J, Slimani L, Chaussain C, Laroche-Raynaud C, Guibaud L, Broissand C, Amiel, Legendre L, Terzi F, Canaud G.
    Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
    Nature 2018 Jun;558(7711):540-546 with commentary Jun;558(7711):523-526
  • 2016

  • Delville M, Baye E, Durrbach A, Audard V, Kofman T, Braun L, Olagne J, Nguyen C, Deschênes G, Moulin B, Delahousse M, Kesler-Roussey G, Beaudreuil S, Martinez F, Rabant M, Grimbert P, Gallazzini M, Terzi F, Legendre C, Canaud G.
    Costimulation (B7-1) blockade does not improve post transplant nephrotic syndrome from recurrent FSGS.
    J Am Soc Nephrol. 2016 Aug;27(8):2520-7
  • 2014

  • Canaud G, Bienaimé F, Tabarin F, Bataillon G, Seilhean D, Noel LH, Dragon-Durey MA, Snanoudj R, Friedlander G, Halbwachs-Mecarelli L, Legendre C, Terzi F.
    Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome.
    N Engl J Med. 2014 Jul 24;371(4):303-312, with commentary Jul 24;371(4):369-371
  • Canaud G, Dejucq-Rainsford N, Avettand-Fenoël V, Viard JP, Anglicheau D, Bienaimé F, Muorah M, Galmiche L, Gribouval O, Noël LH, Satie AP, Martinez F, Sberro-Soussan R, Scemla A, Gubler MC, Friedlander G, Antignac C, Onetti Muda A, Terzi F, Rouzioux C, Legendre C.
    The kidney as a reservoir for HIV-1 after renal transplantation.
    J Am Soc Nephrol. 2014 Feb;25(2):407-19, with commentary Feb;25(2):212-5
  • 2013

  • Canaud G, Bienaimé F, Treins C, Viau A, Nguyen C, Berissi S, Giannakakis K, Muda Onetti A, Friedlander G, Legendre C, Pende M, Terzi F.
    Stress-induced Akt2 activation is crucial for podocyte maintenance in chronic kidney disease.
    Nat Med. 2013 Oct;19(10):1288-96, with commentary Oct;19(10):1212-3


  • More information: https://www.ncbi.nlm.nih.gov/pubmed/?term=canaud+g

    Our group is dedicated to decipher the mechanisms underlying the physiopathology of overgrowth syndromes (PROS) in order to improve patient’s condition. We have been working since a long time on the PIK3/AKT/mTOR pathway in the context of kidney diseases but based on a patient experience, we have progressively moved to this new field in 2016.

    In order to achieve our goal, we have 2 sides: the research laboratory and the clinic. Very importantly, we have a very strong interaction between these two entities.

    The laboratory (http://canaudlab.recherche.parisdescartes.fr) is developing new in vitro and in vivo models to better understand disease progression, to identify potential biomarkers and to offer new therapeutic opportunities. To this end, we have engineered multiple genetic mouse models and we are using innovative technology to explore the molecular and structural cellular changes in overgrowth syndromes. Currently, we are trying to understand the impact of PIK3CA mutation on the fate of the different tissues (adipose tissues, bones, vessels…). To support our research, we are lucky enough to have multiple findings including European (ERCs) and Governmental grants but also from private and public Foundation supports and generous donators (i.e. US Cloves community syndrome).

    From the clinical perspective (http://www.maladiesrares-necker.aphp.fr/syndromes-dhypercroissance/), we have created a unit dedicated to patient with overgrowth syndromes. We offer state of the art genotyping and the patients have access on single day to all the specialists (surgeons, geneticists, radiologists, dermatologist, endocrinologists…). This team also includes administrative assistants to organize all the medical appointments, nurses, assistant nurses, physical therapists, psychologists… We just received a EUR 10 Million grant from our Government to accelerate our development. We are seeing French but also patients coming from abroad. Every month, we have a multidisciplinary meeting to discuss all new cases as well as patients necessitating specific advices.

    This is a very exciting Human adventure and if you want to join or visit us do not hesitate to contact me.

    Chercheur statutaire
    Guillaume Canaud
    Chercheur hospitalo-Universitaire
    +33 (0)1 40 61 54 25
    CDI
    Sophia Ladraa
    Ingénieur(e) en biologie
    +33 (0)1 40 61 54 85
    ITA non statutaire
    Charles Bayard
    Ingénieur(e) en techniques biologiques
    +33 (0)1 40 61 54 28
    Célia Chapelle
    Assistant(e) en techniques biologiques
    +33 (0)1 40 61 54 85
    Clara Coquart
    Ingénieur
    +33 (0)6 36 26 80 00
    Rubina Dias Cassaca
    Ingénieur
    Marina Firpion
    Ingénieur
    Clément Hoguin
    Technicien supérieur en techniques biologiques
    +33 (0)1 40 61 54 28
    Hamida Makouf
    Gestionnaire financière
    +33(0)1 40 61 54 85
    Post-doctorant
    Quitterie De Reydet De Vulpillieres
    Post-doctorant(e)
    +33 (0)1 40 61 54 85
    Junna Yamaguchi
    Post-doctorant(e)
    +33 (0)1 40 61 54 28
    Doctorant
    Antoine Fraissenon
    Doctorant(e)
    Gabriel Morin
    Doctorant(e)
    +33 (0)1 40 61 54 28
    Lola Zerbib
    Doctorant(e)
    +33 (0)1 40 61 54 28
    Adresse

    Notice: Undefined variable: contact_addr in /homepages/40/d483507699/htdocs/location.php on line 21
    Parrain(s)
    S.A.R. la Princesse Caroline de Hanovre qui, à travers la Fondation Princesse Grace, soutient déjà la recherche medicale et tout ce qui contribue à soulager les enfants malades en France et dans le monde, a accepté de s'engager à nos cotés pour que ce centre de medecine moleculaire, tourné entre autres vers les pathologies des enfants, prenne de vitesse les maladies et continue à relever les defis actuels.

    INEM - Organigramme